Abattis Bioceuticals Corp. (OTCPK:ATTB.F) entered into an agreement to acquire Select Strains Inc. for $3.5 million on November 21, 2018. Under the terms, Select Strains will exchange the ownership of its proprietary strain portfolio, seed inventory and clone catalogue for 41.6 million shares at a price of $0.12 per share. There is also a finder’s fee of 10% also paid in shares. The transaction is subject to approval from exchange and exemption of distribution of the consideration shares from the prospectus and registration requirements under applicable Canadian securities laws, consummation of due diligence, approval from Board of Directors of Select Strains Inc., among others. Abattis Bioceuticals Corp. (OTCPK:ATTB.F) completed the acquisition of Select Strains Inc. on November 22, 2018.